Single answer
Is Agenus Inc (AGEN) a buy or sell?
4starter turns market data into one clear verdict you can act on.
Create a free account to save tickers and track your signals.
Log in to turn on watchlist alerts.
Decision snapshot
Everything you need to act fast, in one glance.
What is the conclusion?
Right now our advanced algorithms say:
Do analysts agree?
We compare consensus targets with today's price.
Consensus target for Agenus Inc is $7.33, which is $4.19 (133.44%) above the current price today's price.
Low target: $7.00 | High target: $8.00
Company snapshot
A quick overview of the business and its public profile.
Agenus Inc a clinicalstage immunooncology company discovers and develops immunooncology products in the United States and internationally The company offers Retrocyte Display an antibody expression platform for the identification of fully human and humanized monoclonal antibodies and display technologies It develops vaccine programs comprising Prophage vaccine candidate and QS21 Stimulon adjuvant a saponinbased vaccine adjuvant The company also develops Balstilimab an antiPD1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer AGEN1181 an antiCTLA4 monospecific antibody that is in Phase 12 clinical trial AGEN2373 an antiCD137 monospecific antibody that is in Phase 1 clinical trial AGEN1423 a tumor microenvironment conditioning antiCD73TGFss TRAP bifunctional antibody that has completed Phase 1 clinical trial AGEN1777 an antiTIGIT bispecific antibodies and AGEN1327 a human monoclonal antibody In addition the company develops INCAGN1876 an antiGITR monospecific antibody INCAGN1949 an antiOX40 monospecific antibody INCAGN2390 an antiTIM3 monospecific antibody INCAGN2385 an antiLAG3 monospecific antibody MK4830 a monospecific antibody targeting ILT4 AGENT 797 an iNKT cells that is in Phase 1 clinical trial for solid tumors multiple myeloma and viral ARDS as well as in clinical stage to treat hematological malignancies and multiple myelomaB cells and AGEN1884 a firstgeneration antiCTLA4 monospecific antibody Agenus Inc operates under ASV Agenus AutoSynVax EVAMPLIX MiNK PSV PhosPhoSynVax Prophage Retrocyte Display and Stimulon trademarks It has collaborations with Incyte Corporation Merck Sharpe Dohme Recepta Biopharma SA and Gilead Sciences Inc The company was formerly known as Antigenics Inc and changed its name to Agenus Inc in January 2011 Agenus Inc was founded in 1994 and is headquartered in Lexington Massachusetts
Website: https://www.agenusbio.com
Rates and inflation backdrop
US inflation for September 2025 was 0.31%. Over the last 12 months, inflation is 3.02%. The 10-year yield is 4.14 and is down -0.0800 over the last 30 days.
Inflation sensitivity
Debt ratio: 0.29. Cash flow to debt ratio: -2.39. Net profit margin: -162.74%. Inflation risk score: high (0.85/1).
Dividend history check
We cannot find any recorded dividends paid in our systems.
Trading liquidity
Yes, the average daily trading liquidity for Agenus Inc is $2.1M. You should therefore be able to get in and out of your positions relatively fast.
10-year return check
On Agenus Inc, 2015-12-31 had a stock price of $90.80. If you invested back then, your return now would be a loss of $87.66 per share or 96.54%.
Why this answer
We combine price momentum, volatility, and trend signals to simplify the decision to one word.
Signal engine scans price, trend, and momentum indicators.
Targets and sentiment are checked against the live quote.
We keep the output simple: buy, sell, or hold.
Analyst consensus
How Wall Street targets compare to today's price.